CR9560A - Antagonistas y agonistas de piperazin-piperidina del receptor 5-ht1a - Google Patents
Antagonistas y agonistas de piperazin-piperidina del receptor 5-ht1aInfo
- Publication number
- CR9560A CR9560A CR9560A CR9560A CR9560A CR 9560 A CR9560 A CR 9560A CR 9560 A CR9560 A CR 9560A CR 9560 A CR9560 A CR 9560A CR 9560 A CR9560 A CR 9560A
- Authority
- CR
- Costa Rica
- Prior art keywords
- ht1a
- piperazin
- agonists
- piperidine
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invencion se refiere a nuevos compuestos de piperazin-piperidina. Los compuestos son utiles como agentes de enlace a 5-HT1A, particularmente como agonistas y antagonistas del receptor 5-HT1A. Estos compuestos son utiles en el tratamiento de trastornos del sistema nervioso central, tales como trastornos de cognicion, trastorno de ansiedad, depresion y disfuncion sexual.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68946905P | 2005-06-10 | 2005-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR9560A true CR9560A (es) | 2008-02-20 |
Family
ID=37530084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR9560A CR9560A (es) | 2005-06-10 | 2007-12-05 | Antagonistas y agonistas de piperazin-piperidina del receptor 5-ht1a |
Country Status (20)
Country | Link |
---|---|
US (1) | US7671056B2 (es) |
EP (1) | EP1888559A2 (es) |
JP (1) | JP2008543782A (es) |
KR (1) | KR20080021134A (es) |
CN (1) | CN101243073A (es) |
AR (1) | AR055059A1 (es) |
AU (1) | AU2006257874A1 (es) |
BR (1) | BRPI0613491A2 (es) |
CA (1) | CA2611711A1 (es) |
CR (1) | CR9560A (es) |
EC (1) | ECSP088094A (es) |
GT (1) | GT200600255A (es) |
IL (1) | IL187972A0 (es) |
MX (1) | MX2007015678A (es) |
NO (1) | NO20076344L (es) |
PE (1) | PE20070069A1 (es) |
RU (1) | RU2007146543A (es) |
TW (1) | TW200800959A (es) |
WO (1) | WO2006135839A2 (es) |
ZA (1) | ZA200710699B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200800959A (en) | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
TW200811144A (en) * | 2006-06-09 | 2008-03-01 | Wyeth Corp | Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline |
TW200808741A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
TW200808740A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof |
TW200808730A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | Process for synthesizing piperazine-piperidine compounds |
PE20080332A1 (es) * | 2006-06-09 | 2008-05-05 | Wyeth Corp | Metodos para mejoramiento de funcion cognitiva |
US20080262228A1 (en) * | 2006-11-28 | 2008-10-23 | Wyeth | Metabolites of 5-fluoro-8- quinoline and methods of preparation and uses thereof |
AR063983A1 (es) * | 2006-11-28 | 2009-03-04 | Wyeth Corp | Formulacion de liberacion controlada de agonistas y antagonistas de piperazina -piperidina del receptor 5-ht1a que tienen una disolucion intestinal mejorada |
AR065376A1 (es) * | 2007-02-16 | 2009-06-03 | Wyeth Corp | Formulacion de pastillas de liberacion sostenida de antagonistas y agonistas de piperazina - piperidina del receptor 5 ht1a que tienen disolucion instestinal mejorada |
WO2010033045A1 (en) * | 2008-09-16 | 2010-03-25 | Igor Anatolievich Pomytkin | Compositions and methods for prevention or treatment of beta amyloid deposition |
WO2010081851A1 (en) | 2009-01-14 | 2010-07-22 | Genoscience Pharma | Piperidin-4-ylpiperazine compounds for the treatment of hcv infection |
CN101797223B (zh) * | 2009-02-06 | 2012-05-23 | 上海交通大学医学院 | 石杉碱甲眼用制剂及其应用 |
WO2011011060A1 (en) * | 2009-07-22 | 2011-01-27 | Puretech Ventures | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
US10933020B2 (en) | 2018-09-28 | 2021-03-02 | Karuna Therapeutics, Inc. | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2908952C3 (de) * | 1979-03-07 | 1981-12-03 | Gerhard Hug Gmbh, 7801 Umkirch | Drainagevorrichtung |
US4624954A (en) * | 1985-12-20 | 1986-11-25 | American Home Products Corporation | 6,7,8,9-tetrahydro-10-methylpyrido[1,2-a]indol-9-amines and derivatives thereof, useful for the treatment of cognitive impairments |
US4665183A (en) * | 1985-12-20 | 1987-05-12 | American Home Products Corp. | Process for preparing 6,7,8,9-tetrahydro-10-methylpyrido[1,2-a]indol-9-amines and derivatives thereof useful for the treatment of cognitive impairments |
US5219857A (en) * | 1986-10-16 | 1993-06-15 | American Cyanamid Company | Method of treating cognitive and related neural behavioral problems |
US4904658A (en) * | 1988-04-15 | 1990-02-27 | American Cyanamid Company | Substituted-6H,8H-pyrimido-[1,2,3-cd]purine-8,10-(9H)-diones and substituted-6H,10H-pyrimido[1,2-cd]purin-10-ones |
US5260331A (en) * | 1989-01-02 | 1993-11-09 | John Wyeth & Brother Limited | Composition for treating depression with (S- or O-heteroaryl)alkyl amines |
US5422355A (en) * | 1989-06-02 | 1995-06-06 | John Wyeth & Brother, Limited | Composition for treating depression with (N-heteroaryl)alkylamines |
DK0510068T3 (da) * | 1990-01-11 | 1999-10-25 | Upjohn Co | Nye 6,7,8,9-tetrahydro-3H-benz(e)indol-heterocycler med virkning på centralnervesystemet |
AU645681B2 (en) * | 1991-05-02 | 1994-01-20 | John Wyeth & Brother Limited | Piperazine derivatives |
GB9125615D0 (en) * | 1991-12-02 | 1992-01-29 | Wyeth John & Brother Ltd | Amines |
PT1156043E (pt) | 1992-07-24 | 2004-03-31 | Univ California | Drogas que aumentam as respostas sinapticas mediadas por receptores de ampa |
TW444018B (en) | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
CZ284157B6 (cs) | 1992-12-17 | 1998-08-12 | Pfizer Inc. | Pyrazolové a pyrazolopyrimidinové sloučeniny jako takové a pro léčbu chorob a farmaceutické prostředky na jejich bázi |
NZ256620A (en) | 1992-12-17 | 1996-05-28 | Pfizer | Pyrazole derivatives; compounds and pharmaceutical compositions containing them; intermediate compounds |
ATE177101T1 (de) | 1992-12-17 | 1999-03-15 | Pfizer | Pyrrolopyrimidine als crf antagonisten |
TW336932B (en) | 1992-12-17 | 1998-07-21 | Pfizer | Amino-substituted pyrazoles |
GB9411099D0 (en) | 1994-06-03 | 1994-07-27 | Wyeth John & Brother Ltd | Piperazine derivatives |
US5650409A (en) | 1995-06-02 | 1997-07-22 | Cortex Pharmaceuticals, Inc. | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
GB9514901D0 (en) | 1995-07-20 | 1995-09-20 | American Home Prod | Piperazine derivatives |
US5736543A (en) | 1996-04-03 | 1998-04-07 | The Regents Of The University Of California | Benzoxazines for enhancing synaptic response |
SK282725B6 (sk) * | 1996-05-31 | 2002-11-06 | Pharmacia & Upjohn Company | Arylom substituované cyklické amíny ako selektívne D3 ligandy dopamínu |
US5891885A (en) | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
US6329368B1 (en) * | 1997-05-09 | 2001-12-11 | The Regents Of The University Of California | Endocrine modulation with positive modulators of AMPA type glutamate receptors |
ZA991301B (en) | 1998-02-18 | 1999-09-13 | Neurosearch As | Glutamate receptor modulators. |
US6124278A (en) | 1998-04-03 | 2000-09-26 | The Regents Of The University Of California | Acylbenzoxazines for enhancing synaptic response |
SE9804126D0 (sv) | 1998-11-27 | 1998-11-27 | Astra Ab | New pharmaceutical composition |
US6313126B1 (en) * | 1999-01-07 | 2001-11-06 | American Home Products Corp | Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression |
WO2000040554A1 (en) | 1999-01-07 | 2000-07-13 | American Home Products Corporation | Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression |
OA12245A (en) | 2000-04-10 | 2003-11-10 | Pfizer Prod Inc | Benzoamide piperidine compounds as substance P antagonists. |
DE10043659A1 (de) * | 2000-09-05 | 2002-03-14 | Merck Patent Gmbh | Arylpiperazinderivate |
IL145209A0 (en) * | 2000-09-06 | 2002-06-30 | Pfizer Prod Inc | Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
EP1203584A1 (en) | 2000-10-13 | 2002-05-08 | M.D.M. S.r.l. | Cholinergic precursor (in particular choline alfoscerate) associated with an acetylcholinesterase inhibitor (such as rivastigmine, donepezil) |
US6469007B2 (en) * | 2000-11-28 | 2002-10-22 | Wyeth | Serotonergic agents |
US20060287335A1 (en) * | 2000-11-28 | 2006-12-21 | Wyeth | Serotonergic agents for treating sexual dysfunction |
CA2436526C (en) * | 2000-12-13 | 2010-10-19 | Wyeth | Heterocyclic sulfonamide inhibitors of beta amyloid production |
UA73619C2 (en) * | 2000-12-13 | 2005-08-15 | Pfizer Prod Inc | Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment |
US6780860B2 (en) | 2001-04-26 | 2004-08-24 | Wyeth | Azabicyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-ht1a antagonists |
WO2002088132A1 (en) | 2001-04-26 | 2002-11-07 | Wyeth | Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline as 5-ht1aantagonists |
AR035083A1 (es) | 2001-07-25 | 2004-04-14 | Wyeth Corp | Derivados azaheterociclilmetilicos de 7,8-dihidro-6h-5-oxa-1-aza-fenantreno, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de un medicamento antidepresivo e intermediarios |
US20030060513A1 (en) * | 2001-09-27 | 2003-03-27 | Arneric Stephen P. | Pharmaceutical composition |
DE10217006A1 (de) | 2002-04-16 | 2003-11-06 | Merck Patent Gmbh | Substituierte Indole |
US6982268B2 (en) * | 2002-05-08 | 2006-01-03 | Neurogen Corporation | Substituted imidazolylmethyl pyridine and pyrazine derivatives GABAA receptor ligands |
UA78999C2 (en) * | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
TW200401641A (en) * | 2002-07-18 | 2004-02-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands |
CN101099734A (zh) | 2002-08-15 | 2008-01-09 | 惠氏公司 | 用于治疗体温调节机能障碍的5HT2a受体的激动作用 |
US7153849B2 (en) | 2002-09-12 | 2006-12-26 | Wyeth | Antidepressant arylpiperazine derivatives of hetrocycle-fused benzodioxans |
US20040147581A1 (en) | 2002-11-18 | 2004-07-29 | Pharmacia Corporation | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy |
AU2003298664A1 (en) | 2002-11-20 | 2004-06-15 | Cypress Bioscience, Inc. | Treatment of cognitive dysfunctions' |
US7227023B2 (en) | 2003-04-30 | 2007-06-05 | Wyeth | Quinoline 3-amino chroman derivatives |
US7276603B2 (en) | 2003-05-02 | 2007-10-02 | Wyeth | Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use |
US20050032873A1 (en) * | 2003-07-30 | 2005-02-10 | Wyeth | 3-Amino chroman and 2-amino tetralin derivatives |
EP1648904B1 (en) * | 2003-07-31 | 2007-08-22 | Wyeth | N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands |
DK1541197T3 (da) | 2003-12-02 | 2009-06-15 | Pharmaneuroboost N V | Anvendelse af pipamperon og en SNDRI, SNRI eller SSRI til behandling af humörsvingninger eller angstlidelser |
MY179926A (en) | 2003-12-08 | 2020-11-19 | Wyeth Corp | Process for the preparation of tubulin inhibitors |
CA2553291A1 (en) * | 2004-01-29 | 2005-09-09 | Pfizer Products Inc. | Combination of .gamma.-aminobutyric acid modulators and 5-ht1b receptor antagonists |
JP2007526312A (ja) * | 2004-03-02 | 2007-09-13 | ワイス | 神経保護および/または神経再生剤としての非免疫抑制性イムノフィリンリガンド |
CA2556622A1 (en) * | 2004-03-02 | 2005-09-15 | Wyeth | Macrolides and methods for producing same |
US20050215561A1 (en) * | 2004-03-19 | 2005-09-29 | Krishnendu Ghosh | Pharmaceutical dosage forms and compositions |
TWI391387B (zh) * | 2004-05-12 | 2013-04-01 | Eisai R&D Man Co Ltd | 具有哌啶環之吲哚衍生物 |
DE602005012825D1 (de) * | 2004-06-16 | 2009-04-02 | Wyeth Corp | Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren |
EP1756087B1 (en) * | 2004-06-16 | 2009-10-07 | Wyeth | Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase |
EP1799264A2 (en) | 2004-10-08 | 2007-06-27 | Neuromolecular Pharmaceuticals Inc | Methods and compositions for treating migraine pain |
AU2006214454B2 (en) * | 2005-02-15 | 2011-05-19 | Jazz Pharmaceuticals, Inc. | Dosage form and method for sustained release of a substituted pyrazine compound |
TW200800959A (en) | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
JP4796927B2 (ja) * | 2005-11-28 | 2011-10-19 | 株式会社豊田中央研究所 | クロック信号出力回路 |
TW200808740A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof |
TW200808741A (en) | 2006-06-09 | 2008-02-16 | Wyeth Corp | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
PE20080332A1 (es) | 2006-06-09 | 2008-05-05 | Wyeth Corp | Metodos para mejoramiento de funcion cognitiva |
TW200808730A (en) | 2006-06-09 | 2008-02-16 | Wyeth Corp | Process for synthesizing piperazine-piperidine compounds |
AR063983A1 (es) | 2006-11-28 | 2009-03-04 | Wyeth Corp | Formulacion de liberacion controlada de agonistas y antagonistas de piperazina -piperidina del receptor 5-ht1a que tienen una disolucion intestinal mejorada |
-
2006
- 2006-06-08 TW TW095120358A patent/TW200800959A/zh unknown
- 2006-06-09 CA CA002611711A patent/CA2611711A1/en not_active Abandoned
- 2006-06-09 BR BRPI0613491-2A patent/BRPI0613491A2/pt not_active Application Discontinuation
- 2006-06-09 US US11/450,942 patent/US7671056B2/en not_active Expired - Fee Related
- 2006-06-09 RU RU2007146543/04A patent/RU2007146543A/ru not_active Application Discontinuation
- 2006-06-09 CN CNA2006800292484A patent/CN101243073A/zh active Pending
- 2006-06-09 KR KR1020087000800A patent/KR20080021134A/ko not_active Application Discontinuation
- 2006-06-09 JP JP2008516005A patent/JP2008543782A/ja active Pending
- 2006-06-09 WO PCT/US2006/022719 patent/WO2006135839A2/en active Application Filing
- 2006-06-09 MX MX2007015678A patent/MX2007015678A/es not_active Application Discontinuation
- 2006-06-09 AU AU2006257874A patent/AU2006257874A1/en not_active Abandoned
- 2006-06-09 PE PE2006000646A patent/PE20070069A1/es not_active Application Discontinuation
- 2006-06-09 GT GT200600255A patent/GT200600255A/es unknown
- 2006-06-09 EP EP06772861A patent/EP1888559A2/en not_active Withdrawn
- 2006-06-12 AR ARP060102469A patent/AR055059A1/es unknown
-
2007
- 2007-12-05 CR CR9560A patent/CR9560A/es not_active Application Discontinuation
- 2007-12-06 IL IL187972A patent/IL187972A0/en unknown
- 2007-12-07 ZA ZA200710699A patent/ZA200710699B/xx unknown
- 2007-12-11 NO NO20076344A patent/NO20076344L/no not_active Application Discontinuation
-
2008
- 2008-01-10 EC EC2008008094A patent/ECSP088094A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA2611711A1 (en) | 2006-12-21 |
KR20080021134A (ko) | 2008-03-06 |
CN101243073A (zh) | 2008-08-13 |
AR055059A1 (es) | 2007-08-01 |
MX2007015678A (es) | 2008-02-20 |
RU2007146543A (ru) | 2009-07-20 |
IL187972A0 (en) | 2008-03-20 |
US7671056B2 (en) | 2010-03-02 |
ZA200710699B (en) | 2009-05-27 |
WO2006135839A3 (en) | 2007-11-22 |
GT200600255A (es) | 2007-07-19 |
WO2006135839A2 (en) | 2006-12-21 |
BRPI0613491A2 (pt) | 2011-01-11 |
AU2006257874A1 (en) | 2006-12-21 |
JP2008543782A (ja) | 2008-12-04 |
US20070027160A1 (en) | 2007-02-01 |
TW200800959A (en) | 2008-01-01 |
NO20076344L (no) | 2008-02-27 |
ECSP088094A (es) | 2008-02-20 |
EP1888559A2 (en) | 2008-02-20 |
PE20070069A1 (es) | 2007-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR9560A (es) | Antagonistas y agonistas de piperazin-piperidina del receptor 5-ht1a | |
CO6361994A2 (es) | Antagonistas del receptor de orexina de isonicotinamida | |
GT200500297A (es) | Sintesis asimetrica de dehidrobenzofuranos sustituidos | |
CL2008002246A1 (es) | Uso de compuestos derivados de benzamida para tratar trastornos del sistema nervioso central seleccionados entre depresion, ansiedad trastornos psicoticos, trastornos neurologicos, epilepsia, trastornos cardiovasculares, diabetes, dislipidemias, entre otros; compuestos derivados de benzamida; composicion farmaceutica; y uso de la composicion. | |
UY30829A1 (es) | Compuestos agonistas y antagonistas del receptor de esfinfosina-1-fosfato | |
CL2011001263A1 (es) | Compuestos derivados de pirimidinonas opcionalmente sustituidas; composicion farmaceutica que los comprende; y su uso como inhibidores de fosfodiesterasa 1 (pde1) para el tratamiento de enfermedades que involucran trastornos de la trayectoria intracelular del receptor de dopamina d1 como parkinson, alzheimer, depresion, enfermedad bipolar, hipertension, glaucoma. | |
CR20110455A (es) | Derivados de indol como antagonistas del receptor crth2 | |
CO6511237A2 (es) | Dihidrobenzocicloalquiloximetl-oxazolopirimidinonas sustituidas, preparacion y uso de las mismas | |
SV2005002025A (es) | 2, 3, 4, 5-tetrahidro-1h-benzo[d]azepinas 6-sustituidas como agonistas del receptor 5-ht2c - ref. x-16115 | |
CY1110882T1 (el) | Ανταγωνιστες υποδοχεων ορεξινης υποκατεστημενης διαζεπανης | |
CL2009000943A1 (es) | Metodos de preparacion de compuestos intermediarios del tipo pirazoles condensados para la preparacion de moduladores de los receptores de serotonina. (divisional solicitud n° 2384-04) | |
CL2008002864A1 (es) | Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros. | |
CR20140085A (es) | Inhibidores de pde10 de pirimidina | |
CL2008002268A1 (es) | Compuestos derivados de amidas, moduladores del receptor taar1; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, entre otros. | |
PA8795601A1 (es) | Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3 | |
UA106873C2 (uk) | Сполуки заміщених діазепанів як антагоністи орексинових рецепторів | |
CL2007003065A1 (es) | Compuestos derivados de benzodioxano, agonista 5ht2c, composicion farmaceutica que lois comprende; y sus uso en el tratamiento de un trastorno psicotico, ansiedad, depresion, trastorno bipolar, sindrome premenstrual, entre otros | |
CL2011002382A1 (es) | Uso de un compuesto derivado de quinazolina-2,4-diona para el tratamiento y/o la prevencion de trastornos asociados al sistema nervioso central y/o al sistema nervioso periferico, preferentemente trastornos asociados a esquizofrenia, enfermedad de parkinson y enfermedad de alzheimer. | |
IL206359A0 (en) | Sulfonamides as orexin antagonists | |
CR10062A (es) | Composiciones y metodos de tratamiento para trastornos del sistema nervioso central | |
PA8790101A1 (es) | Derivados de aminoalquilazol como antagonistas de histamina-3 | |
GT200800052A (es) | Compuestos triciclicos utiles como agonistas de recepciones de oxitocina | |
CL2012001092A1 (es) | Compuestos derivados de 1-oxo-2-aza-espirolo 4.5- dec-7-il -amida, moduladores del receptor de glutamato metabotropico 5( mglu5 o mglur5); composicion farmaceutica: utiles en el tratamiento de trastornos cognitivos, neurodegenerativos, psiquiatricos o neurologicos, tales como ansiedad, esquizofrenia, alzheimer, entre otros. | |
GT200300045A (es) | Nuevos derivados de tiazol como antagonistas del receptor npy | |
BRPI0916657A2 (pt) | pirrolidin-3-ilmetil-amina como antagonistas de orexina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |